These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 36518297)

  • 41. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
    Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
    Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
    Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
    Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
    Ning Y; Li Y; Wang H
    Front Genet; 2023; 14():1108167. PubMed ID: 36713082
    [No Abstract]   [Full Text] [Related]  

  • 46. Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma.
    Zhai S; Li Y; Yang Y; Lang W; Liu X; Liu K; Qu J; Zhu L
    Front Immunol; 2024; 15():1361657. PubMed ID: 39108273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer.
    Zhou Z; Song Q; Yang Y; Wang L; Wu Z
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.
    Yin X; Jiang K; Zhou Z; Yu H; Yan D; He X; Yan S
    Oxid Med Cell Longev; 2023; 2023():3878796. PubMed ID: 36713030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer.
    Fei Y; Cao D; Dong R; Li Y; Wang Z; Gao P; Zhu M; Wang X; Zuo X; Cai J
    Clin Transl Oncol; 2024 Oct; 26(10):2718-2737. PubMed ID: 38703335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
    Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
    Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
    Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
    BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
    Zhong A; Chen T; Xing Y; Pan X; Shi M
    Front Immunol; 2021; 12():758648. PubMed ID: 34745134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.
    Zhao H; Xie R; Zhang C; Lu G; Kong H
    Front Genet; 2022; 13():989460. PubMed ID: 36159971
    [No Abstract]   [Full Text] [Related]  

  • 54. Type-1 Na
    Zhou YT; Chen H; Ai M; Li SS; Li BY; Zhao Y; Cai WW; Hou B; Ni LL; Xu F; Qiu LY
    Life Sci; 2021 Aug; 278():119613. PubMed ID: 34000263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
    Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
    Front Immunol; 2021; 12():653836. PubMed ID: 33897701
    [No Abstract]   [Full Text] [Related]  

  • 56. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
    Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cathepsin V is correlated with the prognosis and tumor microenvironment in liver cancer.
    Liu J; Zhang W; Wang Z; Wang Y; Li T; Wang Y; Ding J; Ning B
    Mol Carcinog; 2024 Mar; 63(3):400-416. PubMed ID: 38051285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
    He D; Zhang X; Tu J
    Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.
    Yu S; Yang Y; Yang H; Peng L; Wu Z; Sun L; Wu Z; Yu X; Yin X
    Sci Rep; 2023 May; 13(1):7560. PubMed ID: 37161008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.